GlassScriptPhysician profile
Steven M Solomon
NPI 1225060551
$8,698.40
in general payments reported to CMS, 2019-2025
33 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $693 · 2021: $1,084 · 2022: $1,547 · 2023: $1,187 · 2024: $1,026 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855 · Education: $35.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.49 |
| Education | $35.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,274.95 | 2019-2025 | Argos, Rocklatan, Clareon |
| Abbvie INC. | $1,290.41 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $495.43 | 2022-2025 | Xiidra, Miebo, Ic-8 Apthera Iol |
| Oyster Point Pharma, INC. | $483.27 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $410.50 | 2019-2025 | |
| Allergan, INC. | $385.43 | 2020-2022 | |
| Horizon Therapeutics Plc | $370.28 | 2019-2022 | |
| Sight Sciences, INC. | $322.79 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $291.36 | 2021-2022 | |
| Dompe US, INC. | $262.76 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $248.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $222.74 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $221.55 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $183.89 | 2019-2020 | |
| Ocular Therapeutix, INC. | $159.00 | 2019-2025 | Dextenza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $154.61 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $121.84 | 2025 | Xdemvy |
| Amgen INC. | $121.13 | 2024 | |
| Carl Zeiss Meditec, INC. | $119.88 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $111.85 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $105.25 | 2020-2021 | |
| Shire North American Group INC | $67.02 | 2019 | |
| Btg International INC. | $54.06 | 2019 | |
| Rxsight INC | $46.87 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Rayner Intraocular Lenses Limited | $36.11 | 2023-2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Eyepoint US, INC. | $32.95 | 2019 | |
| Glaukos Corporation | $29.41 | 2021 | |
| Spark Therapeutics, INC. | $18.45 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.36 | 2019 | |
| Tearlab Corp | $14.31 | 2023 | Tearlab Osmolarity System |
| Harrow Eye, LLC | $13.78 | 2024 | Iheezo |
| Optos, INC. | $6.44 | 2019 | |
| New World Medical,INC. | $6.19 | 2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.